Cancers 2017, 9(7), 94; https://doi.org/10.3390/cancers9070094
Targeting Platelets for the Treatment of Cancer
1
Faculty of Health Sciences, Curtin University, Perth 6100, Australia
2
Curtin Health Innovation Research Institute (CHIRI), Curtin University, Perth 6100, Australia
3
School of Biomedical Sciences, Curtin University, Perth 6100, Australia
*
Author to whom correspondence should be addressed.
Academic Editor: Samuel C. Mok
Received: 30 June 2017 / Revised: 18 July 2017 / Accepted: 19 July 2017 / Published: 22 July 2017
Abstract
The majority of cancer-associated mortality results from the ability of tumour cells to metastasise leading to multifunctional organ failure and death. Disseminated tumour cells in the blood circulation are faced with major challenges such as rheological shear stresses and cell-mediated cytotoxicity mediated by natural killer cells. Nevertheless, circulating tumour cells with metastatic ability appear equipped to exploit host cells to aid their survival. Despite the long interest in targeting tumour-associated host cells such as platelets for cancer treatment, the clinical benefit of this strategy is still under question. In this review, we provide a summary of the latest mechanistic and clinical evidence to evaluate the validity of targeting platelets in cancer. View Full-TextKeywords:
cancer; cancer therapy; platelet; antiplatelet
▼
Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Elaskalani, O.; Berndt, M.C.; Falasca, M.; Metharom, P. Targeting Platelets for the Treatment of Cancer. Cancers 2017, 9, 94.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.